Go further with cancer screening

We can now treat cancer far more effectively, but we can’t treat what we haven’t found. And while doctors can test individually for 5 specific cancers today, more than 70% of cancer deaths are caused by cancers without recommended screening tests.1,2*

*Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on the estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).

Now there’s a proactive tool to screen for cancer

The Galleri test can be taken annually as a simple blood test and screens for a “fingerprint” of many of the deadliest cancers before they become symptomatic, including those with no recommended screening tests today.1,2,3

About the Galleri test
What does Galleri screen for?

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Galleri Studio Amelia White Product 8745

Who is the Galleri test for?

The Galleri test is recommended for adults with an elevated risk for cancer, such as those age 50 or older.

  • The Galleri test is available by prescription only.

  • Use of the Galleri test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Age is the biggest risk factor for cancer. Adults over age 50 are 13 times more likely to have cancer compared to people under the age of 50.4

Certain factors, in addition to age 50+, further increase cancer risk5:

  • Diabetes
  • Obesity (BMI ≥ 30)
  • Current or previous smokers
white man with short gray hair in gray top and jeans sitting on a couch in front of an open window with his arm around a blonde woman in blue jumpsuit
a bald Black man in a denim button up shirt talking to his partner in their kitchen, a Black woman wearing black cat eye glasses and a blue and pink striped shirt, with a cup of coffee and a tablet on the counter in front of them

Patients

Patients

I am interested in learning more about the Galleri test

white male doctor in lab coat and stethoscope sitting behind a desk and talking to a white blonde female patient in a blue striped shirt

Healthcare Providers

Healthcare Providers

I am a healthcare provider interested in offering the Galleri test to my patients

Black woman in a white polka dot shirt with a tan jacket smiling and sitting at a table with a notebook and pen talking to an Asian woman in a blue and black shirt

Employers

Employers

I represent an employer interested in offering the Galleri test to my organization’s employees

group of healthcare professionals talking and sitting at a table in front of a window with tablets and notepads

Health Systems

Health Systems

I represent a health system interested in making the Galleri test available to my patient population

Have more questions?

Please answer the following questions to fill in the appropriate form.
 

You can also contact us at (833) 694‑2553 or use the chat feature on the bottom-right of this page for additional help.

  1. What describes you best?

  2. What are you looking for?

  3. Fill in the form

    By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

    Billing Support

    This form is for billing questions only. If you need general customer support, please choose one of the other forms or use the chat option at the bottom of your screen.

    By submitting this form, you agree to GRAIL’s use of this information to contact you. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

    By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

    By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

    Please login to the Provider Portal if you are already an ordering provider.

    By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

    By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

    By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

    By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

    Do you represent a first responder or firefighter organization? Use this form instead.

    By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

    By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

    This form is meant for firefighter and first responder organizations only

    By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

Learn how screening with Galleri has made a difference for these patients

Share your story
  • Jack Testimonial

    Patient testimonial: Jack

    Cancer Signal Detected

  • Neil2

    Testimonial: Neil

    Cancer Signal Detected

  • Mike Testimony

    Patient testimonial: Mike

    Cancer Signal Detected

  • Rich S Taci

    Patient testimonial: Rich & Staci

    Cancer Signal Detected

  • Cindy

    Patient testimonial: Cindy

    Cancer Signal Detected

  • Dave video poster

    Patient testimonial: Dave

    Cancer Signal Detected

  • Jennifer Testimonial poster

    Patient testimonial: Jennifer

    No Cancer Signal Detected

  • Jonathan Testimonial Lyphoma

    Patient testimonial: Jonathan

    Cancer Signal Detected

  • Rich testimonials

    Patient testimonial: Rich

    Cancer Signal Detected

  • Cindy testimonial preview

    Patient testimonial: Cindy

    Cancer Signal Detected

  • Mary patient vid

    Patient testimonial: Mary and her doctor, Robert Korolevich, MD

    Cancer Signal Detected

  • “ There are a couple ways to go through life and I am choosing to just embrace it and have all the fun I can. And Galleri gave that to me. ”

    Mary

  • Roger testimonial

    Patient testimonial: Roger

    Cancer Signal Detected

  • Valerie

    Patient testimonial: Valerie

    Cancer Signal Detected

  • “ I feel like this test was made for me and I appreciate it so much. I’m going to be able to live my life because we found it so soon. ”

    Valerie

  • patient story video still of Keith and his wife on a walk

    Patient testimonial: Keith

    No Cancer Signal Detected

  • Patient story video still closeup of Tami

    Patient testimonial: Tami

    No Cancer Signal Detected

1 / 17

We collaborated with leading cancer institutes to study the Galleri test:

Supported by robust clinical data, the Galleri test has been studied in multiple clinical trials with over 20,000 participants.3,6

Explore Galleri Test Performance
Text reading: "GRAIL collaborated with leading cancer institutes to study the Galleri test" followed by logos for the Cleveland Clinic, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Intermountain Healthcare, Icahn School of Medicine at Mount Sinai, Sutter Health, UHN Princess Margaret Cancer Centre, Benoroya Research Institute Virginia Mason, Sarah Cannon, Hartford HealthCare Cancer Institute, The US Oncology Network, Knight Cancer Institute, The Christ Hospital Lindner Research Center

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screenings. [cited 2023 Oct 23]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
  2. American Cancer Society Cancer Facts and Figures 2023. Available at: http://www.cancer.org/content/.... GRAIL, Inc. Data on file GA-2021-0065
  3. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
  4. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER Research Limited-Field Data, 21 Regs, 2020 Nov Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released 2021 Apr, based on the 2020 Nov submission. [Risk Factor Data on file: American Cancer Society Cancer Prevention Studies II/III.]
  5. American Association for Cancer Research. Cancer progress report 2023. https://cancerprogressreport.aacr.org/progress/
  6. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi:10.1016/S0140-6736(23)01700-2